Alkermes plc (ALKS)
NASDAQ: ALKS · IEX Real-Time Price · USD
24.68
+0.24 (0.98%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Alkermes Revenue
In the year 2023, Alkermes had annual revenue of $1.66B with 49.61% growth. Revenue in the quarter ending December 31, 2023 was $377.48M with 23.89% year-over-year growth.
Revenue (ttm)
$1.66B
Revenue Growth
+49.61%
P/S Ratio
2.48
Revenue / Employee
$792,098
Employees
2,100
Market Cap
4.12B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.66B | 551.61M | 49.61% |
Dec 31, 2022 | 1.11B | -61.96M | -5.28% |
Dec 31, 2021 | 1.17B | 135.00M | 13.00% |
Dec 31, 2020 | 1.04B | -132.19M | -11.29% |
Dec 31, 2019 | 1.17B | 76.67M | 7.01% |
Dec 31, 2018 | 1.09B | 190.90M | 21.13% |
Dec 31, 2017 | 903.37M | 157.68M | 21.15% |
Dec 31, 2016 | 745.69M | 117.36M | 18.68% |
Dec 31, 2015 | 628.34M | 9.55M | 1.54% |
Dec 31, 2014 | 618.79M | 43.24M | 7.51% |
Mar 31, 2013 | 575.55M | 185.57M | 47.59% |
Mar 31, 2012 | 389.98M | 203.34M | 108.95% |
Mar 31, 2011 | 186.64M | 8.36M | 4.69% |
Mar 31, 2010 | 178.28M | -148.56M | -45.45% |
Mar 31, 2009 | 326.84M | 86.12M | 35.78% |
Mar 31, 2008 | 240.72M | 752.00K | 0.31% |
Mar 31, 2007 | 239.97M | 73.36M | 44.04% |
Mar 31, 2006 | 166.60M | 90.48M | 118.85% |
Mar 31, 2005 | 76.13M | 37.07M | 94.92% |
Mar 31, 2004 | 39.05M | -8.21M | -17.37% |
Mar 31, 2003 | 47.27M | -6.84M | -12.63% |
Mar 31, 2002 | 54.10M | -1.93M | -3.44% |
Mar 31, 2001 | 56.03M | 33.11M | 144.45% |
Mar 31, 2000 | 22.92M | -10.97M | -32.37% |
Mar 31, 1999 | 33.89M | 8.31M | 32.47% |
Mar 31, 1998 | 25.59M | 5.76M | 29.04% |
Mar 31, 1997 | 19.83M | 3.91M | 24.55% |
Mar 31, 1996 | 15.92M | 2.02M | 14.49% |
Mar 31, 1995 | 13.90M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Perrigo Company | 4.66B |
PACS Group | 3.11B |
Integer Holdings | 1.60B |
Merit Medical Systems | 1.26B |
iRhythm Technologies | 492.68M |
Ultragenyx Pharmaceutical | 434.25M |
Insmed | 305.21M |
Alvotech | 93.38M |
ALKS News
- 3 days ago - Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 - PRNewsWire
- 9 days ago - Alkermes to Report First Quarter Financial Results on May 1, 2024 - PRNewsWire
- 18 days ago - Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia - PRNewsWire
- 19 days ago - Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society - PRNewsWire
- 7 weeks ago - Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors - PRNewsWire
- 2 months ago - Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 - PRNewsWire
- 2 months ago - Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 - PRNewsWire
- 4 months ago - Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference - PRNewsWire